// App-Quantinova.ai

2074 : Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: A phase 2 historically controlled trial.

Researchers

Presenter

  • Andrew Jacob Brenner

Principal Investigators

  • Yael Chava Cohen

  • James J. Vredenburgh

  • Katherine B Peters

  • Lakshmi Nayak

  • Deborah T. Blumenthal

  • Felix Bokstein

  • Eyal Breitbart

  • Livnat Bangio

  • Naamit Sher

  • Andrea R Leubitz

  • Shlomit Yust-Katz

  • Idit Peretz

  • Laurence S Freedman

  • Liraz Olmer

  • Patrick Y. Wen

Medical Centers

  • University of Texas Health Science Center San Antonio, San Antonio, TX

  • VBL Therapeutics, Or Yehuda, Israel

  • St Francis Hospital and Medical Group, Hartford, CT

  • Duke University Medical Center, Durham, NC

  • Dana-Farber Cancer Institute, Boston, MA

  • Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel

  • Rabin Medical Center, Petach Tikvah, Israel

  • Rabin Medical Center, Petach Tikvah, Israel

  • The Gertner Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel

Locations

  • United States

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Glioblastoma

Biomarkers

  • N/A

Drug/Treatment

  • Bevacizumab

  • Ofranergene obadenovec

Outcome

  • N/A

Study Design

  • Controlled

  • Cohort

Phase

  • II

Study Id's

  • NCT01260506

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved